A sulforaphane-based pharmaceutical is slated to begin trials for prostate cancer [86] following preliminary studies showing diminished Nrf2 signaling in prostate cancer that is restored by sulforaphane treatment [87]. The gene discussed is NFE2L2; the disease is Familial prostate cancer.